Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917413 | 0.96 | TBXAS1 (0.47) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL31157063 | 0.91 | BLM (0.41) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL31157064 | 0.91 | BLM (0.41) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL31157050 | 0.91 | BLM (0.41) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL31157055 | 0.91 | BLM (0.41) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL30959045 | 0.91 | BLM (0.41) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL5520693 | 0.85 | CYP2C19 (0.50) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 | |
| SCHEMBL9181319 | 0.84 | CYP2C19 (0.56) | CYP2C19TBXAS1CYP4F2CYP4A11MME | |
| SCHEMBL186819 | 0.83 | CYP2C19 (0.44) | CYP2C19TBXAS1CYP4F2CYP4A11MME | |
| SCHEMBL9182839 | 0.82 | CYP2C19 (0.60) | CETPCYP2C19TBXAS1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713476-B2 | SUBSTITUTED LACTAM; GAMMA-SECRETASE INHIBITOR; DECREASES PRODUCTION OF BETA-AMYLOID; TREATMENT FOR ALTZHEIMER'S AND DOWN'S SYNDROME | DUPONT PHARMACEUTICALS COMPANY | 2004-03-30 | — | — | US | disclosed |
| CN-1434803-A | Cyclic lactams as inhibitors os A-alpha protein production | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | CN | disclosed |
| EP-1268434-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-23 | — | — | US | disclosed |
| WO-2001074784-A1 | CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | APP, BACE1, APH1A | CETP 563/4885CYP2C19 1748/4885TBXAS1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.